G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
- Jupiter Bioventures will Gain Exclusive Rights for the Clinical Development, Regulatory Submissions, and Commercialization of Lerociclib for Radioprotection in the US, Europe, Japan, and All Other...
Jupiter Bioventures David Buttaro Jack Bailey Genor Biopharma Nathaniel David Gain Exclusive Rights For The Clinical Development
Source: marketscreener.com